| Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis SM Rowe, SL Heltshe, T Gonska, SH Donaldson, D Borowitz, D Gelfond, ... American journal of respiratory and critical care medicine 190 (2), 175-184, 2014 | 522 | 2014 |
| Residual weighted learning for estimating individualized treatment rules X Zhou, N Mayer-Hamblett, U Khan, MR Kosorok Journal of the American Statistical Association 112 (517), 169-187, 2017 | 256 | 2017 |
| Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis MM Treggiari, G Retsch-Bogart, N Mayer-Hamblett, U Khan, M Kulich, ... Archives of pediatrics & adolescent medicine 165 (9), 847-856, 2011 | 240 | 2011 |
| Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor SL Heltshe, N Mayer-Hamblett, JL Burns, U Khan, A Baines, BW Ramsey, ... Clinical infectious diseases 60 (5), 703-712, 2015 | 211 | 2015 |
| Pseudomonas aeruginosa In Vitro Phenotypes Distinguish Cystic Fibrosis Infection Stages and Outcomes N Mayer-Hamblett, M Rosenfeld, RL Gibson, BW Ramsey, HD Kulasekara, ... American journal of respiratory and critical care medicine 190 (3), 289-297, 2014 | 134 | 2014 |
| Home monitoring of patients with cystic fibrosis to identify and treat acute pulmonary exacerbations. eICE study results N Lechtzin, N Mayer-Hamblett, NE West, S Allgood, E Wilhelm, U Khan, ... American journal of respiratory and critical care medicine 196 (9), 1144-1151, 2017 | 123 | 2017 |
| GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator … SM Rowe, SL Heltshe, T Gonska, SH Donaldson, D Borowitz, D Gelfond, ... Am J Respir Crit Care Med 190 (2), 175-84, 2014 | 104 | 2014 |
| Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis N Mayer‐Hamblett, RA Kronmal, RL Gibson, M Rosenfeld, ... Pediatric pulmonology 47 (2), 125-134, 2012 | 92 | 2012 |
| Pseudomonas aeruginosa Phenotypes Associated With Eradication Failure in Children With Cystic Fibrosis N Mayer-Hamblett, BW Ramsey, HD Kulasekara, DJ Wolter, LS Houston, ... Clinical infectious diseases 59 (5), 624-631, 2014 | 77 | 2014 |
| Multicenter intestinal current measurements in rectal biopsies from CF and non-CF subjects to monitor CFTR function JP Clancy, RD Szczesniak, MA Ashlock, SE Ernst, L Fan, DB Hornick, ... PloS one 8 (9), e73905, 2013 | 61 | 2013 |
| Cystic fibrosis pulmonary exacerbations attributable to respiratory syncytial virus and influenza: a population-based study R Somayaji, CH Goss, U Khan, M Neradilek, KM Neuzil, JR Ortiz Clinical Infectious Diseases 64 (12), 1760-1767, 2017 | 58 | 2017 |
| Head and neck free flap reconstruction in patients older than 80 years PK Bhama, SA Patel, U Khan, AD Bhrany, ND Futran Journal of reconstructive microsurgery, 523-530, 2014 | 55 | 2014 |
| GOAL (the G551D Observation-AL) Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Pseudomonas aeruginosa in cystic fibrosis patients with G551D … SL Heltshe, N Mayer-Hamblett, JL Burns, U Khan, A Baines, BW Ramsey, ... Clin Infect Dis 60 (5), 703-12, 2015 | 54 | 2015 |
| Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis SL Heltshe, U Khan, V Beckett, A Baines, J Emerson, DB Sanders, ... Journal of Cystic Fibrosis 17 (3), 341-347, 2018 | 48 | 2018 |
| Effects of an antioxidant-enriched multivitamin in cystic fibrosis. A randomized, controlled, multicenter clinical trial SD Sagel, U Khan, R Jain, G Graff, CL Daines, JM Dunitz, D Borowitz, ... American journal of respiratory and critical care medicine 198 (5), 639-647, 2018 | 42 | 2018 |
| Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in … N Lechtzin, N West, S Allgood, E Wilhelm, U Khan, N Mayer-Hamblett, ... Contemporary Clinical Trials 36 (2), 460-469, 2013 | 36 | 2013 |
| A comparison of clinic and home spirometry as longtudinal outcomes in cystic fibrosis A Paynter, U Khan, SL Heltshe, CH Goss, N Lechtzin, NM Hamblett Journal of Cystic Fibrosis 21 (1), 78-83, 2022 | 34 | 2022 |
| Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: results from the prospect study M Shaw, U Khan, JP Clancy, SH Donaldson, SD Sagel, SM Rowe, ... Journal of Cystic Fibrosis 19 (6), 931-933, 2020 | 33 | 2020 |
| Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial M Anstead, SL Heltshe, U Khan, JT Barbieri, M Langkamp, G Döring, ... Journal of Cystic Fibrosis 12 (2), 147-153, 2013 | 33 | 2013 |
| Clinical effectiveness of lumacaftor/ivacaftor in patients with cystic fibrosis homozygous for F508del-CFTR. A clinical trial SD Sagel, U Khan, SL Heltshe, JP Clancy, D Borowitz, D Gelfond, ... Annals of the American Thoracic Society 18 (1), 75-83, 2021 | 31 | 2021 |
